Publications

TitleAbstractYear
Filter
PMID
Filter
hydroxychloroquine use against sars-cov-2 infection in non-human primates.coronavirus disease 2019 (covid-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. among these candidates, hydroxychloroquine (hcq) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (sars-cov-2)-the virus that causes covid-19-worldwi ...202032698191
chloroquine does not inhibit infection of human lung cells with sars-cov-2.the coronavirus disease 2019 (covid-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2), has been associated with more than 780,000 deaths worldwide (as of 20 august 2020). to develop antiviral interventions quickly, drugs used for the treatment of unrelated diseases are currently being repurposed to treat covid-19. chloroquine is an anti-malaria drug that is used for the treatment of covid-19 as it inhibits the spread of sars-cov-2 in the african green ...202032698190
establishment of an african green monkey model for covid-19.severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is responsible for an unprecedented global pandemic of covid-19. animal models are urgently needed to study the pathogenesis of covid-19 and to screen candidate vaccines and treatments. nonhuman primates (nhp) are considered the gold standard model for many infectious pathogens as they usually best reflect the human condition. here, we show that african green monkeys support a high level of sars-cov-2 replication and develop pronounced ...202032511377
intranasal exposure of african green monkeys to sars-cov-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.we recently reported the development of the first african green monkey (agm) model for covid-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 (sars-cov-2). here, we followed up on this work by assessing an i.n. particle only route of exposure using the lma mucosal atomization device (mad). six agms were infected with sars-cov-2; three animals were euthanized near the peak stage of virus replication (day 5) and th ...202032818211
intranasal exposure of african green monkeys to sars-cov-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.we recently reported the development of the first african green monkey (agm) model for covid-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 (sars-cov-2). here, we followed up on this work by assessing an i.n. particle only route of exposure using the lma mucosal atomization device (mad). six agms were infected with sars-cov-2; three animals were euthanized near the peak stage of virus replication (day 5) and th ...202032811514
small particle aerosol exposure of african green monkeys to mers-cov as a model for highly pathogenic coronavirus infection.emerging coronaviruses are a global public health threat because of the potential for person-to-person transmission and high mortality rates. middle east respiratory syndrome coronavirus (mers-cov) emerged in 2012, causing lethal respiratory disease in »35% of cases. primate models of coronavirus disease are needed to support development of therapeutics, but few models exist that recapitulate severe disease. for initial development of a mers-cov primate model, 12 african green monkeys were expos ...202032744989
Displaying items 1 - 6 of 6